In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.
‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...
Clinerion is deploying Volv’s AI algorithms across its hospital network as part of a recently announced strategic collaboration that includes plans to bring an ‘enhanced value proposition’ to both companies’ expanded client base, says CEO.
The network for clinical and imaging data launches a new ‘Real World Imaging’ offering to complement existing real world evidence – and help overcome the challenges of bias and homogeneity, says CEO.
Increasingly complex clinical trials are putting pressure on CROs to expand their service offerings in what has been a historically monolithic space – with diagnostics also continuing to play a more important role in the market, says industry expert.
908 Devices launches Rebel, a bioprocess analyzer, enabling researchers to conduct their own cell culture media analysis to accelerate process development ‘by weeks’.
Atelerix to work on the development of gel stabilisation technologies enabling room temperature storage of Rexgenero’s cell therapy candidate, under an Innovate UK grant.
Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.
Veeva Systems launches a software application aiming to reduce the time and effort of manual data entry, which will be integrated to its cloud-based suite.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
The multi-stakeholder group is developing a blockchain-powered platform to increase transparency and collaboration in the clinical trial supply chain – and has successfully completed a proof-of-concept project, now looking to next steps.
Onconova to use Mission Bio’s Tapestri targeted single-cell DNA analysis platform to advance its cancer therapy, rigosertib, into Phase III clinical trials.
Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.
Acclinate Genetics launches e-DICT, a clinical trials management system aiming to close the gap between the population rate of minorities in the US and their participation rate in clinical trials.
Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.
HCL Technologies and Oracle Health Sciences announce a collaboration to “bridge the gap” between the potential of mobile health and the realities of adoption, says EVP.
At a time when innovation is rapid, clinical development is evolving at the same pace, and new technologies are bringing disruptive opportunities to research, says AbbVie executive.
Product Specific PTRS, Evaluate’s machine learning platform, aims to help assess the likelihood of a drug reaching the market – managing the risks of drug development.
Immodulon to utilize biomarkers identified by Biodesix’ machine learning platform, aiming to accelerate the clinical development of its pancreatic treatment.
A study by Biofourmis aims to improve patient centricity in the drug approval processes by using wearable technology and mobile software to monitor the quality of life for patients with heart failure.
Insilico Medicine develops a semi-automated contracting system to ease the collaboration process between AI companies and industry partners in the discovery space.
MIT has developed an ‘invisible’ device that provides several benefits over traditional patient data collection methods, including improved biomarker development and the ability to detect changes in behavior – by monitoring patients wirelessly, and through...
A collaboration between Mercachem and Gotham leads to the generation of a molecule library, expected to enable new discovery opportunities in the epitranscriptomic targets space.
Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
Eversana adopts Cryoport’s full suite of logistics services, in an alliance expected to ‘drive synergistic growth’ for both companies and answer regenerative medicine demands.
Sponsors to benefit from more accurate, shorter, and less costly trials through Shimmer Research and ClearSky Medical Diagnostics partnerships, says company executive.
Clinical trials are taking longer, drug development costing more, and the stakeholder group expanding – all compounding to create an "industrywide urgency to streamline how trials are run,” says Veeva VP.
Transforming statistical data into a surrogate endpoint can enable comprehension of trial results sooner than usual, but few make the cut after formal validation, says drug development expert and DIA panelist.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
As regulators work to advance the modern clinical trial, the risk-averse clinical research industry is falling behind in the race to bring new therapies to patients, says an industry expert, echoing the former FDA commissioner’s calls for innovation.
University of Rochester Medical Center joined the global health research network aiming to ‘expand its access to advanced clinical trials’, TriNetX announced.
CRF Bracket is expanding its offering across the Asia-Pacific region with a new Tokyo office to help it better serve the area’s diverse and underserved patient population.
Biomarkers have the potential to improve drug development productivity by 34% over the next five years, during which period pre-screened patient pools and the application of predictive analytics also will help address the increasing complexity of clinical...